190 related articles for article (PubMed ID: 2714049)
1. Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.
Keidan AJ; Sowter MC; Johnson CS; Marwah SS; Stuart J
Clin Sci (Lond); 1989 Apr; 76(4):357-62. PubMed ID: 2714049
[TBL] [Abstract][Full Text] [Related]
2. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease.
Keidan AJ; Franklin IM; White RD; Joy M; Huehns ER; Stuart J
Lancet; 1986 Apr; 1(8485):831-4. PubMed ID: 2870317
[TBL] [Abstract][Full Text] [Related]
3. Preservation of deformability (filterability) of sickle cells by BW12C during progressive deoxygenation.
Kenny MW; Stuart J
Br J Haematol; 1983 Nov; 55(3):465-71. PubMed ID: 6639888
[TBL] [Abstract][Full Text] [Related]
4. Substituted benzaldehydes (12C79 and 589C80) that stabilize oxyhaemoglobin also protect sickle cells against calcium-mediated dehydration.
Stone PC; Nash GB; Stuart J
Br J Haematol; 1992 Jul; 81(3):419-23. PubMed ID: 1390217
[TBL] [Abstract][Full Text] [Related]
5. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia.
Arya R; Rolan PE; Wootton R; Posner J; Bellingham AJ
Br J Haematol; 1996 Jun; 93(4):817-21. PubMed ID: 8703810
[TBL] [Abstract][Full Text] [Related]
6. Effect of polymerization tendency on haematological, rheological and clinical parameters in sickle cell anaemia.
Keidan AJ; Sowter MC; Johnson CS; Noguchi CT; Girling AJ; Stevens SM; Stuart J
Br J Haematol; 1989 Apr; 71(4):551-7. PubMed ID: 2469459
[TBL] [Abstract][Full Text] [Related]
7. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
[TBL] [Abstract][Full Text] [Related]
8. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E; Safo MK; Abdulmalik O; Kato GJ
Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
[TBL] [Abstract][Full Text] [Related]
9. Additive in vitro effects of anti-sickling drugs.
Stuart J; Mojiminiyi FB; Stone PC; Culliford SJ; Ellory JC
Br J Haematol; 1994 Apr; 86(4):820-3. PubMed ID: 7918079
[TBL] [Abstract][Full Text] [Related]
10. Polymerization of sickle cell hemoglobin at arterial oxygen saturation impairs erythrocyte deformability.
Green MA; Noguchi CT; Keidan AJ; Marwah SS; Stuart J
J Clin Invest; 1988 Jun; 81(6):1669-74. PubMed ID: 3384944
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of increased deformability of deoxygenated sickle cells upon oxygenation.
Huang Z; Hearne L; Irby CE; King SB; Ballas SK; Kim-Shapiro DB
Biophys J; 2003 Oct; 85(4):2374-83. PubMed ID: 14507701
[TBL] [Abstract][Full Text] [Related]
12. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.
Rolan PE; Parker JE; Gray SJ; Weatherley BC; Ingram J; Leavens W; Wootton R; Posner J
Br J Clin Pharmacol; 1993 Apr; 35(4):419-25. PubMed ID: 8485022
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte heterogeneity in sickle cell disease: effect of deoxygenation on intracellular polymer formation and rheology of sub-populations.
Keidan AJ; Noguchi CT; Player M; Chalder SM; Stuart J
Br J Haematol; 1989 Jun; 72(2):254-9. PubMed ID: 2757967
[TBL] [Abstract][Full Text] [Related]
15. Bepridil as an antisickling agent: membrane internalization and cell rigidity.
Johnson RM; Acquaye C; Féo C; Sarnaik S
Am J Hematol; 1994 Aug; 46(4):310-8. PubMed ID: 8037182
[TBL] [Abstract][Full Text] [Related]
16. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.
Dufu K; Patel M; Oksenberg D; Cabrales P
Clin Hemorheol Microcirc; 2018; 70(1):95-105. PubMed ID: 29660913
[TBL] [Abstract][Full Text] [Related]
17. Perfluorocarbon compounds: effects on the rheological properties of sickle erythrocytes in vitro.
Reindorf CA; Kurantsin-Mills J; Allotey JB; Castro O
Am J Hematol; 1985 Jul; 19(3):229-36. PubMed ID: 4014223
[TBL] [Abstract][Full Text] [Related]
18. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
Rab MAE; van Oirschot BA; Bos J; Merkx TH; van Wesel ACW; Abdulmalik O; Safo MK; Versluijs BA; Houwing ME; Cnossen MH; Riedl J; Schutgens REG; Pasterkamp G; Bartels M; van Beers EJ; van Wijk R
Am J Hematol; 2019 May; 94(5):575-584. PubMed ID: 30784099
[TBL] [Abstract][Full Text] [Related]
19. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
20. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
